*Refresh the page if the below document does not appear.
Parliamentary panel demands free Cancer treatment from government
A parliamentary committee has asked the Centre to provide free Cancer treatment for patients from middle-class households through a government-funded health insurance scheme and to decrease the cancer diagnostics and treatment services in government and private hospitals.
USFDA gives final approval to Zydus's Silodosin and Pregabalin Capsules
The US drug regulatory authority has given final approval to Zydus Lifesciences to market their two new capsules named Silodosin capsules (4 mg and 8 mg) and Pregabalin capsules (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg).
Entod Pharma to launch GLO special division for glaucoma
Entod pharmaceuticals have announced that the firm is all set to launch its GLO ophthalmic subspeciality division to further expand its business. This division will be focused on the treatment of the major cause of blindness in India, Glaucoma.
Seagen eyes a crucial frontline Indication for Top-Seller Adcetris
Seagen’s plan to expand its Adcetris’ drug market is on track following positive results from the Phase II study. On Monday, the biopharma firm announced Adcetris hit the mark in a multi-part, midstage trial for advanced and early-stage classical Hodgkin lymphoma (cHL).
Fosun to draw on big buyout firms for Gland Pharma
According to some sources, big buyout firms Advent International, Baring Private Equity Asia (now owned by EQT), Bain Capital, Blackstone, Carlyle and KKR are some of those who have been approached to buy the Gland Pharmaceuticals owned by Fosun.
Roche Pharma division head to leave amidst CEO changeover
A few months after the Swiss company announced that its diagnostics division head would take over as chief executive officer (CEO) next year, the present head Bill Anderson has decided to quit the firm to look for opportunities outside of Roche.
Boston Scientific to buy majority stake in China's medical tech company Acotec
As mentioned by the company, US-based
medical device manufacturer Boston
Scientific Corp. is set to make a partial offer
for a majority stake of up to 65% in Chinese
medical technology company Acotec
Scientific’s Holdings.
